Roch Doliveux - UCB SA Insider

UCBJY -- USA Stock  

USD 46.45  0.002  0.0043%

Dr. Roch Doliveux has served as NonExecutive Director of UCB S.A. since April 27, 2017. He served as Chairman of the Executive Committee, Chief Executive Officer, Executive Director of the Company between January 1, 2005 and December 31, 2014. He was Deputy Chairman of Executive Committee, Director General of the Pharma Sector of the Company between October 2003 and January 1, 2005. He is Doctor in Veterinarian Medicine from MaisonsAlfort, Mr. Doliveux is also Laureate of the Faculty of Medicine, Creteil, and holds a Masters of Business Administration from INSEAD or Institut Europeen dAdministration des Affaires, France with distinction. He joined the pharmaceutical industry early, first at CibaGeigy in Switzerland, in Peru and in France, and then at ScheringPlough Corporationrationration in various positions, including President of ScheringPlough International. Then, Roch Doliveux joined the Pierre Fabre group a Chief Executive Officer of Pierre Fabre Pharmaceuticals
Age: 60  Chairman Since 2017      
32 2 559 99 99
Doliveux joined UCB in October 2003 as Director General of the Pharma Sector and Deputy Chairman of the Executive Committee. He became CEO and Chairman of the Executive Committee of UCB on January 1, 2005. He is a member of the Board of Directors of UCB, Member of the Board of Stryker Corporationrationrationration in the United States, as well as a member of the Board of the European Federation of Pharmaceutical Association, the Innovative Medicines Initiative which is a publicprivate partnership between the European Union and EFPIA, WELBIO, the INSEAD International Council and Chairman of the Caring Entrepreneurship Fund .

Roch Doliveux Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of 7.3 % which means that it generated profit of $7.3 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of 15.56 % meaning that it generated $15.56 on every $100 dollars invested by stockholders.
The company has accumulated 1.94 B in total debt with debt to equity ratio (D/E) of 28.0 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. UCB SA has Current Ratio of 1.2 suggesting that it may not have the ability to pay its financial obligations in time and when they become due.

Similar Executives

Found 14 records


Susan KilsbyShire plc
Joshua BogerVertex Pharmaceuticals Incorpor
Jeffrey LeidenVertex Pharmaceuticals Incorpor
Robert BradwayAmgen
David KapplerShire plc
John ShineCSL Limited
JeanJacques BienaimeBioMarin Pharmaceutical
Pierre LapalmeBioMarin Pharmaceutical
Jeppe ChristiansenNovo Nordisk AS
Roy VagelosRegeneron Pharmaceuticals
Stelios PapadopoulosBiogen
Robert HuginCelgene Corporation
John MartinGilead Sciences
Goran AndoNovo Nordisk AS

Entity Summary

UCB SA, a biopharmaceutical company, focuses on the discovery and development of medicines and solutions for people living with severe diseases of the immune system or of the central nervous system. UCB SA was founded in 1928 and is based in Brussels, Belgium. UCB SA operates under Biotechnology classification in USA and traded on OTC Market. It employs 7500 people.UCB SA (UCBJY) is traded on OTC Market in USA. It is located in All?e de la Recherche, 60 and employs 7,500 people.

UCB SA Leadership Team

Pascale Richetta, Executive Vice President Bone Patient Value Unit Head, Member of the Executive Committee
Detlef Thielgen, CFO and Executive VP
Kay Davies, Independent Director
Dirk Teuwen, VP Corporate Societal Responsibility
Anna Richo, Executive VP and General Counsel
Viviane Monges, Independent Non-Executive Director
Gerhard Mayr, Non-Executive Chairman of the Board
Cyril Janssen, Director
Cedric Rijckevorsel, Director
JeanChristophe Tellier, Chairman of the Executive Committee, CEO
Arnoud Calesberg, Non-Executive Director
Mark McDade, COO and Executive VP
Xavier Michel, Vice President and Secretary General
Dhavalkumar Patel, Executive Vice President Chief Scientific Officer, Member of the Executive Committee
Bharat Tewarie, Executive Vice President Chief Marketing Officer
Roch Doliveux, Chairman of the Executive Committee, CEO, Executive Director
Norman Ornstein, Non-Executive Independent Director
Jeff Wren, Executive Vice President Neurology ? Patient Value Unit Head
JeanPierre Kinet, Non-Executive Independent Director
Antje Witte, VP of Investor Relations
Alice Dautry, Independent Director
Harriet Edelman, Non-Executive Independent Director
Ulf Wiinberg, Independent Director
Thomas McKillop, Non-Executive Independent Director
Charl Zyl, Executive Vice President Head of Patient Value Operations, Member of the Executive Committee
France Nivelle, VP Global Communication
Fabrice Enderlin, Executive Vice President - Human Resources & Communication, Member of the Executive Committee
Pierre Gurdjian, Independent Director
Ismail Kola, Chief Scientific Officer, Head of New Medicines Patient Value Unit and Executive VP
Emmanuel Caeymaex, Executive Vice President Immunology - Patient Value Unit Head
Evelyn Bergendal, Non-Executive Vice Chairwoman of the Board
Iris LoewFriedrich, Executive Vice President Chief Medical Officer
CharlesAntoine Janssen, Non-Executive Director
Albrecht Graeve, Non-Executive Independent Director
JeanLuc Fleurial, Executive Vice President Chief Talent Officer, Member of the Executive Committee
Alexander Moscho, Executive Vice President Chief Strategy Officer, Member of the Executive Committee

Stock Performance Indicators

Did you try this?

Run Risk-Return Analysis Now


Risk-Return Analysis

View associations between returns expected from investment and the risk you assume
All  Next Launch Risk-Return Analysis

Also Currentnly Active

Purchased a lot of shares of
few hours ago
Traded for 156.0
Purchased a lot of shares of
few hours ago
Traded for 156.0
Purchased over 300 shares of
few hours ago
Traded for 9.81
Also please take a look at World Market Map. Please also try Fundamentals Matrix module to view fundamentals matrix and analyze how accounts are interrelated and interconnected with each other.